Prostate Cancer UK Logo

Prostate Cancer UK

We want a future where lives are not limited by prostate cancer. We unite the brightest minds in science and healthcare and the most passionate and caring people to help men live long and live well.

About Prostate Cancer UK


Tags: Cancer Health & Medical

Prostate Cancer UK's top priority is funding research to stop prostate cancer killing men. We’re investing millions to find better treatments and better tests that can spot fast-growing cancers early, and could be used in a screening programme to save thousands of lives.

The Prostate Cancer Charity was founded in 1996 by Professor Jonathan Waxman to address the 'Outrageous and arbitrary surgical treatment of men'.

We were the first national organisation for prostate cancer in the UK. Our aim was to improve the care and welfare of those affected by prostate cancer, increase investment in research, and raise public and political awareness of a long-neglected disease.

We started small: five members of staff and with our helpline housed in a small room in Hammersmith hospital. It ran one day a week.

We merged with Prostate Action in 2012 and completely rebranded to form Prostate Cancer UK. In the last 20 years, we’ve invested over £37 million into ground breaking research, and continue to provide award-winning support for men.

We have grown in size, strength and influence but our ambition is the same: to put men at the heart of everything we do.

Your Impact

Men are worth fighting for. It's that simple.

That's why we've invested millions of pounds in research over the last ten years. It’s the reason we provide services to men and their families like our helpline, one-to-one support and information leaflets. Your donations can help us do more.

£10

Could pay for ten microscope slides for scientists researching the effects of new treatments.

£25

Could fund one of our Specialist Nurses for one hour to support men affected by prostate cancer and their families.

£50

Could fund 2.5 hours of research which could be the moment we make a breakthrough in understanding prostate cancer.